JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

Search

Akebia Therapeutics Inc

Aperta

SettoreSettore sanitario

2.99 1.01

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2.93

Massimo

3.03

Metriche Chiave

By Trading Economics

Entrata

-5.9M

247K

Vendite

5.1M

62M

Margine di Profitto

0.395

Dipendenti

181

EBITDA

-6.1M

7.4M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+124.36% upside

Dividendi

By Dow Jones

Utili prossimi

6 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-50M

838M

Apertura precedente

1.98

Chiusura precedente

2.99

Notizie sul Sentiment di mercato

By Acuity

64%

36%

328 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Akebia Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 ott 2025, 22:47 UTC

Acquisizioni, Fusioni, Takeovers

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22 ott 2025, 22:13 UTC

Acquisizioni, Fusioni, Takeovers

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22 ott 2025, 21:20 UTC

Utili

Correction to IBM 3Q Sales Jump Article

22 ott 2025, 20:57 UTC

Utili

SAP Posts Higher 3Q Revenue, Operating Profit

22 ott 2025, 23:46 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

22 ott 2025, 23:46 UTC

Discorsi di Mercato

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22 ott 2025, 23:41 UTC

Discorsi di Mercato

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 ott 2025, 23:38 UTC

Discorsi di Mercato

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 ott 2025, 23:15 UTC

Utili

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22 ott 2025, 22:28 UTC

Discorsi di Mercato

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22 ott 2025, 22:02 UTC

Utili

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22 ott 2025, 21:59 UTC

Acquisizioni, Fusioni, Takeovers

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22 ott 2025, 21:58 UTC

Acquisizioni, Fusioni, Takeovers

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22 ott 2025, 21:57 UTC

Acquisizioni, Fusioni, Takeovers

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22 ott 2025, 21:56 UTC

Acquisizioni, Fusioni, Takeovers

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22 ott 2025, 21:47 UTC

Acquisizioni, Fusioni, Takeovers

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22 ott 2025, 21:47 UTC

Utili

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 ott 2025, 21:47 UTC

Acquisizioni, Fusioni, Takeovers

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22 ott 2025, 21:46 UTC

Acquisizioni, Fusioni, Takeovers

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22 ott 2025, 21:45 UTC

Acquisizioni, Fusioni, Takeovers

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22 ott 2025, 21:45 UTC

Acquisizioni, Fusioni, Takeovers

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22 ott 2025, 21:28 UTC

Discorsi di Mercato
Utili

Correction to Alcoa Tariff Market Talk

22 ott 2025, 21:25 UTC

Utili

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22 ott 2025, 21:17 UTC

Utili

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22 ott 2025, 21:09 UTC

Discorsi di Mercato
Utili

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22 ott 2025, 21:00 UTC

Discorsi di Mercato

ESG Roundup: Market Talk

22 ott 2025, 20:59 UTC

Utili

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 ott 2025, 20:51 UTC

Utili

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

22 ott 2025, 20:44 UTC

Utili

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Confronto tra pari

Modifica del prezzo

Akebia Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

124.36% in crescita

Previsioni per 12 mesi

Media 7 USD  124.36%

Alto 8 USD

Basso 6 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Akebia Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

3

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

2.345 / N/ASupporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

328 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat